Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV

The e-poster presented at EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure reports that 100 percent of patients receiving treatment for as short as six weeks with a triple combination of once-daily (QD) AL-335 800mg and simeprevir (SMV) 75mg with 50mg every other day (QOD) of ODV achieved a sustained viral response 12 weeks after the completion of treatment (SVR12).

Published
9 hours ago
From
Achillion press release
NICE says yes to another hepatitis C drug

NICE has published new draft guidance which recommends sofosbuvir-velpatasvir (Epclusa) – an anti-viral drug that offers patients with chronic hepatitis C a potential cure.

Published
10 hours ago
From
NICE
Exviera, Viekirax regimen shows high SVR in HCV genotype 1b after 8 weeks

New data from the GARNET study — presented today in Paris at the 2016 EASL Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure — showed 98% of patients with hepatitis C virus genotype 1b infection without cirrhosis achieved sustained virologic response 12 weeks after treatment with Exviera plus Viekirax without ribavirin, with some showing high rates after 8 weeks.

Published
10 hours ago
From
Healio
New Study: Negotiated Hepatitis C Prescription Drug Costs in United States Often Lower than in Price-Controlled European Countries and Japan

A new report, "Comparison of Hepatitis C Treatment Costs," shows Hepatitis C drug prices, specifically negotiated by pharmacy benefit managers (PBMs) in Medicare Part D in 2015, were typically lower than prices in Europe and Japan.

Published
20 September 2016
From
Yahoo News
Behind Battle Over Drug Prices, Quiet Money From Big Pharma

Is there a conflict of interest for hepatitis C advocates in accepting funds from pharmaceutical companies and representing the interests of patients when questions of drug pricing and access to treatment are being debated?

Published
19 September 2016
From
Bloomberg
NHS funding cuts ‘forcing people to buy medicine through Facebook’

Patients and researchers say the medicine is safe, however pharmacists have warned that medicine bought online could be placebo pills or contain dangerous ingredients.

Published
16 September 2016
From
The Independent
Inventor of Hepatitis C Cure Wins a Major Prize—and Turns to the Next Battle

Lasker Award winner Michael Sofia created a pill to fight an incurable virus. Now he is setting his sights on another.

Published
13 September 2016
From
Scientific American
Ethiopia unable to provide effective national response to viral hepatitis

Ethiopia still lacks required partnerships and resource mobilization for an effective national health response to viral hepatitis, according to a report published in BMC Public Health.

Published
12 September 2016
From
Healio
UK: More options to be made available to treat hepatitis C

New draft guidance published today from NICE recommends elbasvir-grazoprevir - one of the newer hepatitis C antiviral drugs that can offer patients more effective treatment.

Published
12 September 2016
From
NICE press release
Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV

This ongoing phase 2a study was designed to confirm the required dose and treatment duration for an all-oral combination regimen containing odalasvir (ODV) and AL-335 with or without simeprevir (SMV) for durations of eight or six weeks of treatment in treatment-naïve patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection.

Published
09 September 2016
From
Achillion press release
← First12345...118Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close